February 2007 Oncology News International

News
Article

Cover Story

  • Pancreatic Ca Vaccine Extends Survival After Surgery

Focus on Lung Cancer

  • BB-10901 Compound Delivers Potent Agent to CD56+ Tumors
  • First-line Nab-paclitaxel Shows Efficacy in NSCLC Trials

Focus on Hematology

  • High Response Rate for Lenalidomide Plus Melphalan and Prednisone in Newly Diagnosed Multiple Myeloma Patients

Cancer Care & Economics

  • Billing Plans for Routine Care Essential When Patients Enroll in Clinical Trials
  • RHIOs Allow Exchange of Electronic Info

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content